Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Effects of fibrates in kidney disease: A systematic review and meta-analysis

Jun, Min, Zhu, Bin, Tonelli, Marcello, Jardine, Meg J., Patel, Anushka, Neal, Bruce, Liyanage, Thaminda, Keech, Anthony, Cass, Alan and Perkovic, Vlado (2012). Effects of fibrates in kidney disease: A systematic review and meta-analysis. Journal of the American College of Cardiology,60(20):2061-2071.

Document type: Journal Article

IRMA ID 84473293xPUB46
Title Effects of fibrates in kidney disease: A systematic review and meta-analysis
Author Jun, Min
Zhu, Bin
Tonelli, Marcello
Jardine, Meg J.
Patel, Anushka
Neal, Bruce
Liyanage, Thaminda
Keech, Anthony
Cass, Alan
Perkovic, Vlado
Journal Name Journal of the American College of Cardiology
Publication Date 2012
Volume Number 60
Issue Number 20
ISSN 0735-1097   (check CDU catalogue  open catalogue search in new window)
Scopus ID 2-s2.0-84868533549
Start Page 2061
End Page 2071
Total Pages 10
Place of Publication United States
Publisher Elsevier Inc.
HERDC Category C1 - Journal Article (DIISR)
Abstract Objectives
The purpose of this systematic review and meta-analysis was to determine the efficacy and safety of fibrate therapy in the chronic kidney disease (CKD) population.

Background
Fibrate therapy produces modest cardiovascular benefits in people at elevated cardiovascular risk. There is limited evidence about the clinical benefits and safety of fibrate therapy in the CKD population.

Methods
MEDLINE, EMBASE, and the Cochrane Library were systematically searched (1950 to January 2012) for prospective randomized controlled trials assessing the effects of fibrate therapy compared with placebo in people with CKD or on kidney-related outcomes were included.

Results
Ten studies including 16,869 participants were identified. In patients with mild-to-moderate CKD (estimated glomerular filtration rate [eGFR] ≤60 ml/min/1.73 m2), fibrates improved lipid profiles (lowered total cholesterol [−0.32 mmol/l, p = 0.05] and triglyceride levels [−0.56 mmol/l, p = 0.03] but not low-density lipoprotein cholesterol [−0.01 mmol/l, p = 0.83]; increased high-density lipoprotein cholesterol [0.06 mmol/l, p = 0.001]). In people with diabetes, fibrates reduced the risk of albuminuria progression (relative risk [RR]: 0.86; 95% confidence interval [CI]: 0.76 to 0.98; p = 0.02). Serum creatinine was elevated by fibrate therapy (33 μmol/l, p < 0.001), calculated GFR was reduced (−2.67 ml/min/1.73 m2, p = 0.01) but there was no detectable effect on the risk of end-stage kidney disease (RR: 0.85; 95% CI: 0.49 to 1.49; p = 0.575). In patients with eGFR of 30 to 59.9 ml/min/1.73 m2, fibrates reduced the risk of major cardiovascular events (RR: 0.70; 95% CI: 0.54 to 0.89; p = 0.004) and cardiovascular death (RR: 0.60; 95% CI: 0.38 to 0.96; p = 0.03) but not all-cause mortality. There were no clear safety concerns specific to people with CKD but available data were limited.

Conclusions
Fibrates improve lipid profiles and prevent cardiovascular events in people with CKD. They reduce albuminuria and reversibly increase serum creatinine but the effects on major kidney outcomes remain unknown. These results suggest that fibrates have a place in reducing cardiovascular risk in people with mild-to-moderate CKD.
Keywords chronic kidney disease
fibrate
meta-analysis
systematic review
triglyceride cholesterol
DOI http://dx.doi.org/10.1016/j.jacc.2012.07.049   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 7 Abstract Views  -  Detailed Statistics
Created: Tue, 24 Feb 2015, 12:23:32 CST